Terapia con Mecasermina en pacientes con Síndrome De Laron

Abstract

Introduction: Multiple myeloma is a rare blood neoplasm with common refractoriness cases. Several therapeutic schemes are used to treat this pathology, without great efficacy. Nowadays, the literature identifies CAR-T as a promising option that offers patients safety and improved quality of life. Objective: To determine CAR-T therapy as an alternative for treating refractory multiple myeloma. Methodology: A systematic review was conducted using the PRISMA standard, selecting case-control studies, cohort studies, clinical trials, randomized controlled trials, case reports, and case series published in the last five years. A search equation was developed using the following scientific databases: Scopus, PubMed, and Web of Science. Bias was analyzed using RAYYAN and GRADE, while a contingency table was used to synthesize the results. Results: Twenty-one articles that met the eligibility criteria were considered. The selected studies included 1503 patients. The most common adverse effects were cytokine release syndrome and neurotoxicity syndrome associated with Immune Effector Cells (IEC). Dose heterogeneity was related to their severity, and a granulocyte colony is a promising treatment option. Conclusion: CAR-T therapy was determined to be an alternative treatment for refractory multiple myeloma in adults, and its adverse effects are manageable. However, further clinical trials are needed to substantiate these findings.